Iqvia (IQV) Rating Increased to Buy at Jefferies Financial Group

Share on StockTwits

Iqvia (NYSE:IQV) was upgraded by analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a report released on Friday, MarketBeat.com reports. The firm presently has a $150.00 target price on the medical research company’s stock, up from their prior target price of $136.00. Jefferies Financial Group’s price target suggests a potential upside of 17.93% from the company’s current price. Jefferies Financial Group also issued estimates for Iqvia’s Q4 2018 earnings at $1.37 EPS and FY2018 earnings at $5.14 EPS.

IQV has been the topic of several other reports. Morgan Stanley boosted their target price on shares of Iqvia from $130.00 to $145.00 and gave the company an “overweight” rating in a research note on Monday, December 3rd. Goldman Sachs Group raised shares of Iqvia from a “buy” rating to a “conviction-buy” rating in a research note on Friday, January 11th. Zacks Investment Research raised shares of Iqvia from a “hold” rating to a “buy” rating and set a $142.00 target price on the stock in a research note on Tuesday, October 23rd. Piper Jaffray Companies boosted their target price on shares of Iqvia to $131.00 and gave the company a “neutral” rating in a research note on Tuesday, October 23rd. Finally, Royal Bank of Canada boosted their target price on shares of Iqvia to $137.00 and gave the company an “outperform” rating in a research note on Tuesday, October 23rd. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $139.47.

Shares of NYSE:IQV opened at $127.19 on Friday. Iqvia has a one year low of $91.57 and a one year high of $135.48. The firm has a market cap of $24.82 billion, a PE ratio of 29.17, a P/E/G ratio of 1.58 and a beta of 0.81. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.09 and a quick ratio of 1.09.

Iqvia (NYSE:IQV) last announced its quarterly earnings data on Monday, October 22nd. The medical research company reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $0.03. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The company had revenue of $2.59 billion during the quarter, compared to the consensus estimate of $2.58 billion. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities research analysts expect that Iqvia will post 5.13 EPS for the current year.

In related news, CFO Michael R. Mcdonnell sold 9,500 shares of the stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $128.35, for a total value of $1,219,325.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Group Holdings (Sbs) Advis Tpg sold 3,573,545 shares of the stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $123.72, for a total transaction of $442,118,987.40. The disclosure for this sale can be found here. Insiders sold 6,747,433 shares of company stock valued at $834,836,396 in the last three months. Company insiders own 6.00% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. FMR LLC increased its holdings in shares of Iqvia by 588.8% during the third quarter. FMR LLC now owns 2,989,843 shares of the medical research company’s stock worth $387,902,000 after buying an additional 2,555,776 shares in the last quarter. Steadfast Capital Management LP increased its holdings in shares of Iqvia by 218.4% during the third quarter. Steadfast Capital Management LP now owns 2,796,870 shares of the medical research company’s stock worth $362,866,000 after buying an additional 1,918,336 shares in the last quarter. Third Point LLC acquired a new stake in shares of Iqvia during the third quarter worth approximately $194,610,000. USS Investment Management Ltd increased its holdings in shares of Iqvia by 173.0% during the fourth quarter. USS Investment Management Ltd now owns 1,820,200 shares of the medical research company’s stock worth $211,498,000 after buying an additional 1,153,500 shares in the last quarter. Finally, Capital Research Global Investors increased its holdings in shares of Iqvia by 51.8% during the third quarter. Capital Research Global Investors now owns 3,055,858 shares of the medical research company’s stock worth $396,467,000 after buying an additional 1,042,431 shares in the last quarter. 89.94% of the stock is owned by hedge funds and other institutional investors.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Featured Story: Fiduciary

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.